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Key messages
 ► Severe gout is associated with cardiovascular 
mortality.
 ► achieving and maintaining a serum uric acid target 
below normal levels (<0.36 mmol/l or 6 mg/dl) in 
the first year reduces the risk of dying substantially.
 ► lower uric acid level targets should be recommend-
ed for hyperuricaemic patients with gout. this infor-
mation may help increase adherence to treatment if 
well explained to patients.
AbstrAct
Objective to determine the impact of achieving 
serum uric acid (sUa) of <0.36 mmol/l on overall and 
cardiovascular (cV) mortality in patients with gout.
Methods Prospective cohort of patients with gout 
recruited from 1992 to 2017. exposure was defined as 
the average sUa recorded during the first year of follow-
up, dichotomised as ≤ or >0.36 mmol/l. Bivariate and 
multivariate cox proportional hazards models were used to 
determine mortality risks, expressed Hrs and 95% cis.
Results Of 1193 patients, 92% were men with a mean 
age of 60 years, 6.8 years’ disease duration, an average 
of three to four flares in the previous year, a mean sUa of 
9.1 mg/dl at baseline and a mean follow-up 48 months; 
and 158 died. crude mortality rates were significantly 
higher for an sUa of ≥0.36 mmol/l, 80.9 per 1000 
patient-years (95% ci 59.4 to 110.3), than for an sUa of 
<0.36 mmol/l, 25.7 per 1000 patient-years (95% ci 21.3 
to 30.9). after adjustment for age, sex, cV risk factors, 
previous cV events, observation period and baseline sUa 
concentration, an sUa of ≥0.36 mmol/l was associated 
with elevated overall mortality (Hr=2.33, 95% ci 1.60 to 
3.41) and cV mortality (Hr=2.05, 95% ci 1.21 to 3.45).
Conclusions Failure to reach a target sUa level of 
0.36 mmol/l in patients with hyperuricaemia of gout is an 
independent predictor of overall and cV-related mortality. 
targeting sUa levels of <0.36 mmol/l should be a principal 
goal in these high-risk patients in order to reduce cV 
events and to extend patient survival.
InTROduCTIOn
Gout has emerged as the most common 
inflammatory arthritis in men, as well as one 
of the most common causes of arthritis in 
elderly women in high-income countries1 A 
large body of evidence incriminates gout as 
a major determinant of mortality, both total 
and cardiovascular (CV).2 3 This risk increases 
with the severity of the gout.4 5 Treatment of 
gout has not been consistently associated with 
reductions in mortality6 7 due to the fact that 
serum uric acid (sUA)–mortality associations 
have not been sufficiently explored while on 
therapy.
International guidelines recommend target 
sUA levels of below 0.36 mmol/L (6 mg/
dL) to reduce the frequency of gout flares 
and morbidity,8 9 although many treating 
physicians accept higher threshold values.10 
High baseline sUA levels plus tophi are asso-
ciated with elevated mortality,4 suggesting a 
plausible pathophysiological link between 
greater total body urate load and CV disease. 
It is speculated that patients with sUA levels 
beyond 0.36 mmol/L experience increased 
mortality despite urate-lowering therapy 
(ULT) and, therefore, a target threshold of 
at least <0.36 mmol/L should be set as the 
desired threshold based on this premise.
We recently reported a strong independent 
association between the severity of gout and 
increased mortality,4 but this was during a 
period when the concept of treat-to-target was 
not yet established and the optimal target 
levels were not clearly defined. During this 
period, most patients were on active ULTs 
and patients not on target had short periods 
of follow-up. In this current study, we have 
expanded the primary cohort of patients with 
gout and the period of follow-up in order to 
explore the association of achieved sUA levels 
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with mortality. Our objective was to determine whether 
elevated sUA levels and their pharmacological control 
are associated with increased total and CV mortality.
MeThOds
We conducted a longitudinal prospective study nested in 
a clinical database for which all participants had provided 
consent for data collection.
Patients
All patients with a confirmed diagnosis of gout who 
attended a designated gout clinic at Cruces Hospital from 
1 January 1992 to 31 December 2017 were eligible for 
inclusion. The clinic serves an industrial and suburban 
area from the Basque Country with over 400 000 inhab-
itants and as a regional referral centre for patients with 
difficult to treat gout.
Gout was defined as recurrent acute episodes of joint 
inflammation associated with sustained (>1 year) hyper-
uricaemia (>0.41 mmol/L) and a remission of gout flares 
during follow-up after adequate control of sUA levels. 
For the majority of patients, monosodium urate crystals 
were demonstrated in synovial fluid samples or in mate-
rial aspirated from nodules suspicious to be tophi in 
patients. When such samples for crystal observation were 
unavailable (previous long-term treatment, or rejection 
of consent for aspirating joints or tophi), or ultrasound 
examination did not find neat double contour or topha-
ceous deposits, gout was defined based on the above clin-
ical definition.
All patients with at least one follow-up visit were 
included in the analysis. Patients in whom gout was asso-
ciated with a haematological malignancy or other malig-
nant disease known not to be in remission were excluded 
for this analysis.
Procedures, variables and data collection
Patients included in the study were evaluated at first 
clinic visit (baseline) and at subsequent follow-up visits, 
managed by a single rheumatologist (FPR). At least 
three visits were scheduled for the first year of follow-up. 
Afterwards, follow-up visits were established every 3–12 
months, according to the patient’s clinical status, treat-
ment response and comorbidities. Patients who did not 
attend follow-up visits were assessed periodically for vital 
status. Patients who refused further follow-up at the 
hospital or who were discharged for primary care or to 
other physicians were censored at the last visit for this 
study. The primary endpoint was mortality. The time and 
cause of death were confirmed through medical records, 
patients’ families or local mortality registry if needed.
The principal exposure was sUA level defined as the 
mean sUA concentration recorded in the year following 
the first clinic visit. For all patients, levels were moni-
tored during follow-up, and the average sUA level dichot-
omised as ≤0.36 mmol/L vs >0.36 mmol/L was used as 
explanatory variable.
Baseline data were captured on patient characteris-
tics recorded at first clinic visit. These included data on 
age, sex, body mass index (BMI), previous treatment 
with ULT, number of joints affected at entry, presence of 
subcutaneous tophi, radiographical evidence of gout-re-
lated articular damage, number of gout flares in the 
preceding year, previous diagnosis of CV disease, namely, 
coronary heart disease, heart failure, stroke, peripheral 
vascular disease or current treatment with acenocumarol 
as anticoagulant; loop diuretic use; alcohol intake, 
defined as an average ethanol consumption of ≥20 g/day; 
diabetes mellitus, fasting glucose level of >7.8 mmol/L 
or prescribed insulin or oral antidiabetic drugs; hyper-
tension (HT), systolic blood pressure of >140 mm Hg 
or diastolic blood pressure of >90 mm Hg or on antihy-
pertensive treatment; hyperlipidaemia, total cholesterol 
of >62.4 mmol/L or triglycerides >1.71 mmol/L; or on 
lipid-lowering agents. Kidney function was evaluated at 
baseline by calculating creatinine and urea clearances 
from 24 hours of urinary collections in the first years of 
the cohort, and based on modification of diet in renal 
disease (MDRD) and chronic kidney disease (CKD)-Epi 
equations thereafter. Clinically relevant renal function 
impairment was defined as a creatinine clearance of 
<60 mL/min. In addition, patients were automatically 
classified in the informatics system according to the 
extended Kaiser pyramid into four levels, from low death 
to high death risk, as suggested by the Basque country 
chronic care model.11
Medications for gout were also recorded during 
follow-up. All participants were treated in a similar 
manner that included prophylaxis with low-dose colchi-
cine (0.5–1.0 mg orally once daily) prescribed for 6–12 
months, depending on the presence or absence of 
subcutaneous tophi, respectively, or prednisone (2.5 mg 
PO, two times per day) if colchicine was not tolerated 
or contraindicated in non-diabetic patients. ULTs were 
prescribed to patients with sUA levels over 0.36 mmol/L 
on a shared decision process and doses adjusted during 
follow-up to target sUA levels of 0.36 mmol/L.
statistical analysis
A descriptive analysis was conducted using summary 
statistics, mean or median and SD or IQR, for contin-
uous variables, and frequency tables and percentages, 
for categorical ones. Baseline characteristics were 
compared between patients alive or deceased at the 
end of follow-up. Normally distributed continuous vari-
ables were compared using Student’s t-test with unequal 
variances, and continuous non-parametric variables by 
Kruskal-Wallis and Mann-Whitney U tests. The differ-
ences in frequency of categorical variables were deter-
mined by chi-square and Fisher’s exact tests.
Survival analysis was performed using the Kaplan-Meier 
method. Survival time started at the date of the first clinic 
visit. Differences between patients achieving or not the 
therapeutic goal—sUA of <0.36 mmol/L—during the 
first year, were evaluated by the Mantel-Haenszel statistic 
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Table 1 Description of the sample from the gout clinic at 
Hospital de Cruces
Variable N Value
Sex (male), n (%) 1192 1095 (91.9)
Age (years), m±SD 1192 60.8±13.6
Diagnosis, n (%) 1192   
  Clinical 178 (14.9)
  Microscopy 942 (79.0)
  Ultrasound 72 (6.0)
Disease duration (years), median (P25–P75) 1187 4 (2–10)
Clinical evolution, n (%) 1184   
  Tophi without arthritis 3 (0.2)
  Monoarticular 176 (14.9)
  Oligoarticular 573 (48.4)
  Polyarticular 432 (36.5)
Number of flares in the previous year, 
median (P25–P75)
1179 2 (2–4)
Tophi, n (%) 1191 398 (33.4)
sUA (baseline) (mg/dL), m±SD 1181 9.1±1.5
sUA levels during follow-up after 
optimisation, n (%)
1095   
  <0.36 mmol/L 916 (83.6)
  ≥0.36 mmol/L 179 (16.3)
Comorbidity and risk factors   
  BMI (kg/m2), m±SD 1173 28.1±4.0
  Creatinine (baseline) (mg/dL), m±SD 1176 1.27±0.89
  Creatinine clearance (mL/min), m±SD 1044 73.3±33.0
  Ethanol consumption >20 g/day, n (%) 1171 378 (32.3)
  Arterial hypertension, n (%) 1172 606 (51.7)
  Diabetes, n (%) 1171 235 (20.1)
  Hyperlipidaemia, n (%) 1170 565 (48.3)
  Previous CV event, n (%) 1171 363 (31.0)
  Urate lithiasis, n (%) 1170 97 (8.3)
Treatment 1192   
  Urate-lowering drugs, n (%) 1190 483 (40.5)
First-line treatment, n (%)   
  Without treatment 133 (11.2)
  Allopurinol 740 (62.2)
  Benzbromarone 213 (17.9)
  Febuxostat 104 (8.7)
BMI, body mass index; CV, cardiovascular; m, mean; sUA, serum uric 
acid.
(log-rank test). Total mortality and CV-related mortality 
(stroke, acute myocardial infarction, heart failure, isch-
aemic heart disease, pulmonary thromboembolism and 
unknown cause) were compared between groups. The 
overall mortality rate was calculated as the ratio between 
the number of deaths observed and the cumulative 
survival time, expressed as patient-years.
Bivariate and multivariate Cox proportional hazards 
models were used to determine the variables associated 
with survival. Potential predictive factors in the bivariate 
Cox model were age at disease onset, number of gout 
flares per year, sex, disease duration, BMI, serum creat-
inine and sUA at cohort entry, diuretic use, high blood 
pressure, hyperlipidaemia, diabetes mellitus, presence 
of tophi, prior CV event, ULT, achieving target sUA of 
<6 mg/dL, radiographical involvement, prophylaxis 
with colchicine, anakinra or prednisone, first-line treat-
ment and presentation form. In the multivariate models, 
the role of the Kaiser strata was evaluated as a possible 
confounder or effect modification factor. All the vari-
ables with a p value of <0.10 in the bivariate analysis were 
incorporated into the multivariate models.
Multivariate models were constructed by successive 
inclusion/elimination of variables according to their 
contribution to the dependent variable (mortality). The 
final model is the most parsimonious, that is, the model 
that explains more with fewer variables. In order to take 
into account possible changes in patient management 
during the long observation period of the cohort (1991–
2017), a time period stratification variable was intro-
duced in the models.
We also performed a stepwise regression model to 
compare the results using Akaike’s Information Criteria 
(AIC) and Bayesian Informationc Criteria (BIC) criteria. 
However, these criteria were not finally used, since the 
more parsimonious model with successive manual elim-
ination of variables was chosen to support this selection 
based on clinical reasoning rather than on statistical 
methods. Missing values were not imputed in the models 
and all analyses were performed with STATA V.12. The 
significance limit was set at 0.001.
ResulTs
The cohort included 1193 patients, mostly men (92%), 
with a mean age of 60 years and a disease duration of 6.8 
years, who presented an average of three to four flares 
during the previous year (range 0–66). At cohort entry, 
the mean sUA was 9.1 mg/mL (range 4.8–17.1), and 
the mean creatinine clearance was 73.3 mL/min. Severe 
gout was frequent, as well as polyarticular gout, present 
at entry in 36%, and with tophi observed in 33% of 
cases. The diagnosis was based primarily on microscopy 
(79%), then on clinical data (15%) and less frequently 
on specific ultrasound findings (6%). Regarding comor-
bidity and risk factors, HT was present in 52%, diabetes 
in 20%, lithiasis in 8 %, and 32% consumed alcohol. 
Almost a third of cases (31%) had history of previous CV 
events, and only 40% had received ULT before entering 
the study (see table 1).
Mortality
The mean follow-up was 48.6±49.5 months (median 30, 
range 0–272), with loss to follow-up in 286 cases (24%). 
Only 16.3% of patients could not maintain the sUA target 
of <0.36 mmol/L, despite treatment.
A total of 158 (13%) patients died, of whom 82 did 
so in relation to a CV event. Compared with survivors, 
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Table 2 Baseline characteristics by vital status at the end of follow-up
Variable Alive Dead P value
Age (years) 58 (49–69) 75 (64–80) <0.001
Disease duration (years) 4 (2–10) 4 (2–10) 0.936
Number of flares/previous year 2 (2–4) 3 (2–6) <0.001
Tophi 75 (47.5%) 83 (52.5%) <0.001
sUA (baseline) (mg/dL) 8.7 (8.1–9.7) 9.3 (8.5–10.7) <0.001
Creatinine clearance (mL/min) 75.0 (48.0–98.0) 57.2 (39.7–86.4) <0.001
Clinical evolution <0.001
  Tophi without arthritis 3 (0.3%) –
  Monoarticular 162 (15.8%) 14 (8.9%)
  Oligoarticular 511 (49.8%) 62 (39.2%)
  Polyarticular 350 (34.10%) 82 (51.9%)
First-line treatment <0.001
  Without treatment 120 (11.6%) 13 (8.2%)
  Allopurinol 658 (63.8%) 82 (51.9%)
  Benzbromarone 167 (16.2%) 46 (29.1%)
  Febuxostat 87 (8.4%) 17 (10.8%)
Tophi 315 (30.5%) 83 (52.5%) <0.001
Comorbidity and risk factors
  BMI (kg/m2) 27.8 (25.6–30.4) 27.2 (24.6–30.5) 0.163
  Ethanol consumption >20 g/d 350 (34.5%) 28 (17.8%) <0.001
  Hypertension 484 (47.7%) 122 (77.7%) <0.001
  Diabetes 176 (17.4%) 59 (37.6%) <0.001
  Hyperlipidaemia 505 (49.9%) 60 (38.2%) 0.007
  Previous CV event 259 (25.5%) 104 (66.2%) <0.001
Kaiser strata <0.001
  No risk factors 67 (22.9%) 2 (6.2%)
  1–2 chronic diseases 92 (31.5%) 6 (18.7%)
  Comorbidity (3–4 diseases) 89 (30.5%) 9 (28.1%)
  Frailty (5+ diseases) 44 (15.1%) 15 (46.9%)
Treatment and target
  Urate-lowering drugs 417 (40.3%) 66 (41.8%)
sUA target achieved <0.001
  Yes 806 (85.3%) 110 (73.3%)
  No 139 (14.7%) 40 (26.7%)
Continuous variables are presented as median (IQR).
BMI, body mass index; CV, cardiovascular; sUA, serum uric acid.
patients who died during follow-up were older (median 
75 vs 58), experienced a greater number of flares during 
the previous year (median 3 vs 2), had higher sUA levels 
(median 9.3 vs 8.7), lower creatinine clearance (57 vs 75) 
and had lower alcohol consumption. In addition, polyar-
ticular presentation was more common among decedents 
(51.9% vs 34.1%), as well as the use of benzbromarone 
as first-line treatment (29.1% vs 16.2%), tophi (52.5% vs 
30.6%), HT (77.7% vs 47.7%), diabetes mellitus (37.6% 
vs 17.4%) and previous CV events (66.2% vs 25.5%). 
Deceased cases also had greater baseline comorbidity, 
and 47% of them were in a situation of frailty (≥5 chronic 
diseases) vs 15% of alive. Finally, the proportion of 
patients who did not reach the therapeutic goal (sUA 
<0.36 mmol/L) was significantly higher among those 
who died (26.7% vs 14.7%) (table 2).
All patients were included in the survival analysis 
(n=1192), although 30 were excluded due to lack of 
follow-up (follow-up time=0). Follow-up time was 4830.2 
patient-years (maximum of 22.7 years). Median survival 
was not reached; therefore, we calculated the 25th 
percentile (12 and 19 years for overall and CV mortality, 
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Figure 1 Survival function: overall mortality in persons with 
gout.
Figure 2 Survival function: cardiovascular mortality in 
persons with gout.
Figure 3 Survival function in persons with gout by whether 
the sUA target was achieved or not: overall mortality. sUA, 
serum uric acid.
Figure 4 Survival function in persons with gout according 
to sUA target (<6 vs >6): cardiovascular mortality. sUA, serum 
uric acid.
respectively). The corresponding mortality rate was 
overall 32.7 (95% CI (shaded areas) 28.0 to 38.2) and 
CV-related 17.0 (95% CI (shaded areas) 13.7 to 21.1) per 
1000 patient-years (figures 1 and 2).
The survival function was significantly different by 
whether target sUA was achieved or not (log-rank 
p<0.001), with higher mortality among patients with 
an sUA of ≥0.36 mmol/L both, overall and CV-related 
(figures 3 and 4; shaded areas represent 95% CI).
In the group with an sUA of <0.36 mmol/L, 110 deaths 
occurred during a follow-up time of 4285.6 person-years 
(mortality rate of 25.7 per 1000 person-years; 95% CI 
21.3 to 30.9), whereas in the group with an sUA of 
≥0.36 mmol/L, 40 deaths occurred during 494.2 person-
years (mortality rate 80.9 per 1000 person-years, 95% CI 
59.4 to 110.3).
In univariate analysis, the variables associated with 
higher overall mortality were increasing age, number of 
flares in the previous year, baseline sUA and creatinine, 
HT, diabetes mellitus, previous CV events, diuretic use, 
presence of tophi, radiological involvement and failure 
to achieve the therapeutic goal of 0.36 mmol/L. In the 
multivariate model (n=1068), failure to achieve an sUA 
of <0.36 mmol/L was associated with elevated mortality, 
with an HR of 2.33, and this effect was independent of 
age, the initial sUA levels, previous CV events and year 
of inclusion in the cohort (table 3). The introduction 
of sex and/or disease duration in the final model did 
not modify the overall likelihood of the model or the 
coefficients.
For CV-related mortality, the main determinants in 
the bivariate analysis were age, sex, baseline sUA and 
creatinine, ethanol consumption, HT, hyperlipidaemia, 
previous CV events, diuretic use and tophi. In the multi-
variate analysis, failure to reach an sUA of <0.36 mmol/L 
was associated with increased mortality risk (HR=2.05, 
p=0.007), regardless of age, baseline sUA, previous CV 
events, CV risk factors and strata of observation’s period. 
As in global mortality, the introduction of demographic 
variables, like sex and disease duration, in the final model 
did not modify the obtained results (table 4).
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Table 3 Determinants of overall mortality
Variable
Univariate
HR (95% CI) P value
Multivariate
HR (95% CI) P value
Age* 1.10 (1.08 to 1.12) <0.001 1.08 (1.06 to 1.10) <0.001
Sex (male) 0.44 (0.28 to 0.68) <0.001
Clinical evolution
  Tophi only or mono 1
  Oligo 1.18 (0.66 to 2.10) 0.584
  Polyarticular 2.04 (1.15 to 3.59) 0.014
Disease duration* 0.99 (0.97 to 1.01) 0.491
Number of flares in the previous year 1.03 (1.01 to 1.06) 0.002
sUA (baseline)* 1.33 (1.22 to 1.46) <0.001 1.21 (1.10 to 1.33) <0.001
Tophi 2.21 (1.61 to 3.02) <0.001
Radiological assessment
  Normal 1
  Joint damage 1.79 (1.13 to 2.84) 0.013
Comorbidity and risk factors
  BMI 0.98 (0.94 to 1.03) 0.486
  Creatinine (baseline)* 1.21 (1.10 to 1.32) <0.001
  Ethanol consumption 0.44 (0.29 to 0.67) <0.001
  Hypertension 4.23 (2.89 to 6.17) <0.001
  Diabetes mellitus 2.64 (1.91 to 3.64) <0.001
  Hyperlipidaemia 0.68 (0.49 to 0.94) 0.020
  Previous CV event 6.22 (4.44 to 8.71) <0.001 2.70 (1.82 to 3.98) <0.001
  Diuretic treatment 5.55 (3.99 to 7.71) <0.001
Kaiser strata
  Without risk factors 1
  1–2 chronic diseases 2.16 (0.44 to 10.7) 0.345
  3–4 chronic diseases 3.20 (0.69 to 14.8) 0.137
  ≥5 chronic diseases 9.97 (2.28 to 43.6) 0.002
Follow-up and treatment
Prophylaxis
  None 1
  Anakinra 0.51 (0.10 to 2.66) 0.429
  Colchicine 0.76 (0.30 to 1.97) 0.578
  Prednisone 2.10 (0.50 to 8.83) 0.310
Cochicine
  No 1
  Yes 1.29 (0.86 to 1.94) 0.213
First-line treatment
  Without treatment 1
  Allopurinol 0.34 (0.19 to 0.62] <0.001
  Benzbromarone 0.46 (0.24 to 0.87] 0.017
  Febuxostat 0.79 (0.38 to 1.64] 0.536
  Urate-lowering drugs 0.92 (0.67 to 1.26) 0.606
sUA levels achieved
  Yes 1
Continued
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Variable
Univariate
HR (95% CI) P value
Multivariate
HR (95% CI) P value
  No 2.95 (2.05 to 4.26) <0.001 2.33 (1.60 to 3.41) <0.001
Cohort entry (year period)
  1991–2000 1
  2001–2010 1.78 (1.17 to 2.71) 0.007 1.14 (0.74 to 1.78)1 0.546
  2011–2017 2.68 (1.67 to 4.31) <0.001 1.17 (0.70 to 1.95) 0.543
*Per unit (year, mg/dL).
BMI, body mass index; CV, cardiovascular; sUA, serum uric acid.
Table 3 Continued
dIsCussIOn
In this large prospective cohort study of patients with 
gout, we found that the risks of overall and CV mortality 
were significantly elevated for patients who failed to 
achieve target sUA concentrations of 0.36 mmol/L. These 
risks were substantial with over twofold higher mortality 
compared with similar patients with gout who met target 
UA levels and were not accounted for by demographic 
or clinical factors, including several acute illness indica-
tors. The findings from this study add credence to the 
hypothesis that elevated UA concentrations above 6 mg/
dL contribute substantially to mortality and to shortened 
life spans.
A possible mechanism through which high concentra-
tions of uric acid influence inflammatory responses by 
facilitating interleukin (IL)-1β production in peripheral 
blood mononuclear cells (PBMCs) has been described by 
Crisan et al.12 Hyperuricaemia causes a shift in the IL-1β/
IL-1Ra balance produced by PBMCs after exposure to 
monosodium urate (MSU) crystals and toll-like receptors 
(TLR)-mediated stimuli, and this phenomenon is likely 
to reinforce the enhanced state of chronic inflammation.
In a previous study, we observed an excess mortality 
among patients with gout compared with the general 
population, which was in part related to an excess of CV 
risk factors but also due to the severity of gout as indi-
cated by subcutaneous tophi.4 In the current Cruces 
cohort, we highlight several important new findings. 
First, gouty erosions as detected on X-ray were inde-
pendently predictive of mortality in this new multivari-
able model, whereas gouty tophi detected from clinical 
examination were not. These would suggest that erosive 
radiological changes indicate greater severity of inflam-
mation and urate burden than tophi alone. Interestingly, 
erosive gout is a reflection of tophaceous deposits,13 and 
articular deposits are much more frequent than subcuta-
neous ones.14 15 Second, serum UA levels in the follow-up 
period, beyond baseline levels, continue to exert a signif-
icant predictive impact on future mortality, representing 
the continued risk of long-standing hyperuricaemia.13 16 
Baseline serum UA level relevance may be interpreted 
either as an independent effect or mediated by unap-
parent burden of deposits, as subcutaneous deposition 
may not reflect necessarily what ultrasound or dual-en-
ergy CT studies may disclose.17
Variability in the number of sUA determinations 
during the first year, as well as their timing before or after 
12 months after up-titrating treatment could have some 
effect on mortality. In order to avoid this limitation, all 
patients in the cohort had a minimum of three urate 
(UA) levels during the first year (3, 6 and 12 months). 
Besides, in the majority of patients, follow-up sUA 
levels were obtained after ULT had worked (84% had a 
follow-up time longer than 12 months).
The impact of ULT on CV events is controversial, with 
studies showing allopurinol treatment is associated with 
a reduction in the risk of myocardial infarction18 and 
outweighing the impact of rare serious adverse effects,19 
and other studies showing no impact on CV mortality.20 
In our study. we confirm the beneficial impact of allopu-
rinol and benzbromarone in reducing overall mortality, 
as each of these was associated with improved survival. 
This positive benefit also extended to lower rates of 
CV death, although the level of significance was less 
likely related to the smaller event rate. No safety signal 
was observed for first-line treatment with either allo-
purinol, febuxostat or benzbromarone, as multivariate 
analysis included confounding variables for CV risk 
factors, comorbidity and severity of gout. No benefit was 
observed for colchicine prophylaxis, but the number of 
patients was small and clinically heterogeneous (patients 
not willing to take any more colchicine, with formal 
contraindication, and some exposed to anakinra as 
off-label prophylaxis). Therefore, we are cautious with 
this negative result.
To put things in context, the prevalence of gout in 
adults in the USA has been estimated in 3.7% and the 
prevalence of gout with an indication of ULT in 2.2% 
(4.5 million people).21 Of the latter, target sUA may 
only be achieved in half of the patients.21 Very high sUA 
levels have been reported in association with atherogen-
esis, independently from HT and other CV risk factors.22 
Some concerns have also been raised on the impact of 
excessive lowering of sUA, as studies have shown that 
hypouricaemia is correlated with endothelial dysfunc-
tion.23 The evidence to support this, however, is limited.24 
Taken together, there is increasing evidence to support 
 o
n
 O
ctober 14, 2019 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2019-001015 on 13 O
ctober 2019. Downloaded from
 
8 Pérez ruiz F, et al. RMD Open 2019;5:e001015. doi:10.1136/rmdopen-2019-001015
RMD Open
Table 4 Determinants of CV-related mortality
Variable
Bivariate
HR (95% CI) P value
Multivariate
HR (95% CI) P value
Age* 1.12 (1.09 to 1.14) <0.001 1.08 (1.06 to 1.11) <0.001
Sex (male) 0.30 (0.17 to 0.53) <0.001
Clinical evolution
  Tophi only or mono 1
  Oligo 0.98 (0.43 to 2.27) 0.968
  Polyarticular 2.43 (0.10 to 5.37) 0.028
Disease duration* 0.99 (0.96 to 1.02) 0.527
Number of flares in the previous year 1.03 (1.00 to 1.06) 0.080
sUA (baseline)* 1.39 (1.24 to 1.57) <0.001 1.22 (1.08 to 1.38) 0.001
Tophi 2.83 (1.82 to 4.40) <0.001 1.65 (1.02 to 2.66) 0.040
Radiological assessment
  Normal 1
  Joint damage 2.97 (1.32 to 6.69) 0.009
Comorbidity and risk factors
  BMI 1.01 (0.95 to 1.07) 0.727
  Creatinine (baseline)* 1.21 (1.07 to 1.38) 0.003
  Ethanol consumption 0.35 (0.19 to 0.65) 0.001
  Hypertension 5.83 (3.27 to 10.40) <0.001
  Diabetes mellitus 3.90 (2.52 to 6.04) <0.001 1.69 (1.05 to 2.72) 0.029
  Hyperlipidaemia 0.58 (0.37 to 0.92) 0.022 0.58 (0.35 to 0.95) 0.032
  Previous CV event 10.14 (6.02 to 17.05) <0.001 3.82 (2.08 to 6.99) <0.001
  Diuretic treatment 7.05 (4.40 to 11.32) <0.001
Kaiser strata
  Without risk factors 1
  1–2 chronic diseases 1.45 (0.13 to 16.00) 0.761
  3–4 chronic diseases 3.55 (0.41 to 30.37) 0.248
  ≥5 chronic diseases 9.19 (1.13 to 74.83) 0.038
Follow-up and treatment
Prophylaxis
  None 1
  Anakinra 0.64 (0.06 to 7.14) 0.720
  Colchicine 1.05 (0.24 to 4.54) 0.952
  Prednisone 1.73 (0.16 to 19.11) 0.654
Cochicine
  No 1
  Yes 1.40 (0.81 to 2.44) 0.230
First-line treatment
  Without treatment 1
  Allopurinol 0.40 (0.17 to 0.97) 0.043
  Benzbromarone 0.49 (0.19 to 1.26) 0.140
  Febuxostat 0.81 (0.28 to 2.34) 0.694
  Urate-lowering drugs 1.00 (0.64 to 1.54) 0.992
sUA levels achieved
  Yes 1 1
Continued
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Crystal arthropathies
Variable
Bivariate
HR (95% CI) P value
Multivariate
HR (95% CI) P value
  No 3.27 (2.00 to 5.34) <0.001 2.05 (1.21 to 3.45) 0.007
Cohort entry (year period)
  1991–2000 1 1
  2001–2010 1.57 (0.90 to 2.74) 0.111 0.80 (0.44 to 1.48) 0.486
  
  2011–2017
2.10 (1.09 to 4.03) 0.026 0.73 (0.36 to 1.50) 0.398
No stratified analysis was performed because the Kaiser strata did not modify the risk associated with sUA.
*Per unit (year, mg/dL).
BMI, body mass index; CV, cardiovascular; sUA, serum uric acid.
Table 4 Continued
lower sUA thresholds of at least 6 mg/dL in patients with 
gout to improve survival.
We and others have advocated for earlier intervention 
in gout primarily to avoid exposure to long-standing 
hyperuricaemia and reduce the risk of chronic topha-
ceous gout.25 The treat-to-target strategy represents a global 
effort to improve gout control by reducing acute gout 
flares, preventing chronic tophaceaous gout and its atten-
dant morbidity. The findings from this study also support 
a treat-to target strategy for improving the outcomes of 
patients with gout by preventing low grade inflammation 
and reducing the risks of CV and total mortality.26 27
Our study has some inherent limitations. Patients 
not reaching the target also were the ones with shortest 
follow-up; something hard for us to interpret, and to 
foresee potential biases. Also our models did not adjust for 
smoking or non-steroidal anti-inflammatory drug use due 
to missing data. In addition, the Kaiser Permanente risk 
stratification was used as a measure of comorbidity instead 
of other indices, such as the Charlson index, being the 
former more prone to subjectivity; on the other hand, the 
stratification we used is readily available in all patients, as 
the algorithm used to stratify is embedded in the electronic 
system. Our cohort was derived from patients attending 
a specialist clinic, and may represent a sicker cohort of 
patients than commonly seen in primary care. Neverthe-
less, our objective was not descriptive, but analytical, and we 
cannot think of reasons why this relationship between not 
reaching a sUA target and death may not be replicated in 
other settings. Finally, the design was not that of a clinical 
trial, and treatment may be driven by extraneous factors, 
and even by the availability of medications (benzbromarone 
was not available for some periods of time, then was second 
line after allopurinol, finally febuxostat became available 
in 2010). Others have used propensity-score matching to 
reduce bias attributed to physician prescribing and prac-
tices.20 28 29 However, given that most patients were on ULT 
in our cohort, monitored and treated by same physician, 
and that the associations of UA and death were far stronger 
than with any individual treatment, we believe that the asso-
ciation between UA and mortality is robust. Our cohort was 
established over a long period of time (26 years), during 
which there have possibly been major changes in the 
spectrum of patients with gout and in treatment; that is to 
say, the different time strata may have some effect, such as 
on the CV risk of rheumatoid arthritis. However, in a subse-
quent paper the same group showed that, contrary to RA, 
it did not happen in gout. Nevertheless, our rate of proper 
control is one of the highest ever published and is similar 
throughout the cohort.
On the other hand, the way how patients were treated 
may have changed and may indeed be a predictor of 
mortality. However, there was no signal for mortality for 
any prophylaxis schedule. Therapy was within approved 
label, and therefore, not aggressive.
Finally, the number of flares during therapy is not 
included in the analysis, while the number of flares in the 
precedent year were. This has been considered a surro-
gate, among others, for severity of gout, as an accepted 
outcome by agencies and outcome measures rheumatic 
diseases clinical trials (OMERACT) for trials, and even 
an indication for ULT in the ACR2012 recommenda-
tions.30 31
This study also has several strengths that deserve 
mention. First, most studies that have explored the 
mortality risks of gout have lacked crucial information on 
sUA levels, radiographical evaluation and disease severity 
indicators—tophi and clinical joint involvement.2 The 
Cruces cohort, in contrast, permits a closer explora-
tion of these factors on the gout–mortality relationship. 
Second, all patients underwent serial clinical evaluations 
by a single specialist, reducing the risk of variation in 
disease assessment and facilitating a more homogeneous 
approach to management. Third, the study cohort bene-
fited from a comprehensive assessment of demographic, 
clinical and disease severity indicators, allowing us to 
explore the independence of these factors on mortality 
in adjusted models.
In conclusion, patients with hyperuricaemia of gout 
who fail to achieve guideline-recommended lowering of 
UA to <0.36 mmol/L experience higher rates of total and 
CV mortality that are not explained by prevailing disease 
indicators. The adoption and implementation of ULT 
lowering strategies that lower sUA levels to <0.36 mmol/L 
are likely to confer a survival advantage beyond gout 
control and to improve patient outcomes.
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